Capital Flow Monitor · Sponsors · CIK 1835579
Ikena Oncology, Inc.
645 Summer Street, Suite 101, BOSTON, MA, 02210 · 857-273-8343
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$75.0M
Sold
$0
% sold
0.0%
Investors
0
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-07-18 | D ·current | 506(b) | $75.0M | $0 | 0.0% | 0 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Mark Manfredi — Executive Officer / Director, Boston, MA
- Jotin Marango — Executive Officer, Boston, MA
- Jeffrey Ecsedy — Executive Officer, Boston, MA
-
David Bonita — Director, Boston, MA
6 other raises
- PFARADIGM Health, Inc. $31.1M of $56.1M · 55.4%
- Alpfa Medical, Inc. $80.3M of $100.3M · 80.1%
- OrbiMed Partners II, L.P. $1.78B of —
- Thrombolex, Inc. $32.8M of $51.1M · 64.1%
- Treeline Biosciences, Inc. $200.1M of $250.0M · 80.0%
- Adela, Inc. $25.4M of $27.0M · 94.2%
-
Iain Dukes — Director, Boston, MA
1 other raise
- Angiex, Inc. $22.0M of $28.4M · 77.4%
- Jean-Francois Formela — Director, Boston, MA
- Otello Stampacchia — Director, Boston, MA
- Maria Koehler — Director, Boston, MA
- Richard Wooster — Director, Boston, MA
-
Owen Hughes — Director, Boston, MA
1 other raise
- Stipple Bio, Inc. $65.1M of $100.2M · 65.0%
Placement agents
- Leerink Partners Llc · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.